These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21430221)

  • 1. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.
    Lisiero DN; Soto H; Liau LM; Prins RM
    J Immunol; 2011 May; 186(9):5068-77. PubMed ID: 21430221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
    Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
    J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
    Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
    Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
    Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
    J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
    Kerkar SP; Muranski P; Kaiser A; Boni A; Sanchez-Perez L; Yu Z; Palmer DC; Reger RN; Borman ZA; Zhang L; Morgan RA; Gattinoni L; Rosenberg SA; Trinchieri G; Restifo NP
    Cancer Res; 2010 Sep; 70(17):6725-34. PubMed ID: 20647327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
    Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
    Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
    Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
    Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.
    Cho HI; Reyes-Vargas E; Delgado JC; Celis E
    Cancer Res; 2012 Apr; 72(8):1986-95. PubMed ID: 22367213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
    Mueller K; Schweier O; Pircher H
    Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
    Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
    J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
    Oba T; Hoki T; Yamauchi T; Keler T; Marsh HC; Cao X; Ito F
    J Immunol; 2020 Oct; 205(7):1867-1877. PubMed ID: 32848036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
    Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
    J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.